Transmitted drug resistance to rilpivirine among antiretroviral-naïve patients living with HIV from northern Poland

Journal of the International AIDS Society

Volumn 17, Issue , 2014, Pages

  Parczewski, Miłosz ^a   Urbańska, Anna ^a   Maciejewska, Katarzyna ^a   Witak Jȩdra, Magdalena ^a   Leszczyszyn Pynka, Magdalena ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Drug resistance; HIV 1 non B variants; NNRTI; Rilpivirine; Sequencing; Transmission

Indexed keywords

RILPIVIRINE;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; POLAND; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS GENOME; VIRUS LOAD;

DRUG RESISTANCE; HIV-1 NON-B VARIANTS; NNRTI; RILPIVIRINE; SEQUENCING; TRANSMISSION;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MUTATION; NITRILES; POLAND; PREVALENCE; PYRIMIDINES;

EID: 84899916667     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.17.1.18929     Document Type: Article

References (29)

1. Frentz D, Boucher CA, van de Vijver DA. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. 1AIDS Rev. 2012;14(1):17-27.
2. Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009;200(10):1503-8.
3. SPREAD Programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS. 2008;22(5):625-35.
4. Colafigli M, Torti C, Trecarichi EM, Albini L, Rosi A, Micheli V, et al. Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. Clin Microbiol Infect. 2012;18(8):e299-304.
5. Parczewski M, Leszczyszyn-Pynka M, Bander D, Urbanska A, Boron-Kaczmarska A. HIV-1 subtype D infections among Caucasians from northwestern Poland: phylogenetic and clinical analysis. PLoS One. 2012;7(2):e31674.
6. EACS. Guidelines v 7.0 [Internet]. 2013 [cited 2013 Oct 27]. Available from: http://wwweacsocietyorg/Portals/0/Guidelines-Online-131014pdf
7. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 2012;13(Suppl 2):1-85.
8. Polish Scientific AIDS Society. Principles of care for the HIV-infected patients 2013 (in Polish) [Zasady opieki nad osobami zakazonymi HIV 2013]. Warszawa: PTN AIDS, Eko-Press; 2013.
9. Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr. 2012;60(1):33-42.
10. Ford N, Lee J, Andrieux-Meyer I, Calmy A. Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings. HIV AIDS (Auckl). 2011;3:35-44.
11. Parczewski M. Rilpivirine in the light of the genotypic drug resistance data. HIV AIDS Rev. 2013;12(4):89-92.
12. Johnson VA, Calvez V, Gunthard HF, Paredes R, Pillay D, Shafer RW, et al. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med. 2013;21(1):6-14.
13. Rimsky L, Van Eygen V, Hoogstoel A, Stevens M, Boven K, Picchio G, et al. 96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials. Antivir Ther. 2013;18(8):967-77.
14. Azijn H, Tirry I, Vingerhoets J, de Bethune MP, Kraus G, Boven K, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010;54(2):718-27.
15. Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulie C, Fourati S, et al. Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses. J Antimicrob Chemother. 2013;68(6):1237-42.
16. Reinheimer C, Doerr HW, Sturmer M. Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database. J Clin Virol. 2012;53(3):248-50.
17. Anta L, Llibre JM, Poveda E, Blanco JL, Alvarez M, Perez-Elias MJ, et al. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. AIDS. 2013;27(1):81-5.
18. Bunupuradah T, Ananworanich J, Chetchotisakd P, Kantipong P, Jirajariyavej S, Sirivichayakul S, et al. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01-AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. Antivir Ther. 2011;16(7):1113-21.
19. Vingerhoets J, Rimsky L, Van Eygen V, Nijs S, Vanveggel S, Boven K, et al. Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response. Antivir Ther. 2013;18(2):253-6.
20. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis. 2006;42(11):1608-18.
21. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 2.0. Bioinformatics. 2007;23(21):2947-8. (Pubitemid 350162903)
22. Los Alamos National Laboratory, Theoretical Biology and Biophysics Group. HIV sequence compendium 2012. Los Alamos.
23. Guindon S, Dufayard JF, Lefort V, Anisimova M, Hordijk W, Gascuel O. New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol. 2010;59(3):307-21.
24. Anisimova M, Gascuel O. Approximate likelihood-ratio test for branches: a fast, accurate, and powerful alternative. Syst Biol. 2006 Aug;55(4):539-52. (Pubitemid 43922340)
25. Zaharatos GJ, Wainberg MA. Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication. Ann Med. 2013 May;45(3):236-41.
26. Parczewski M, Leszczyszyn-Pynka M, Bander D, Urbanska A, Stanczak G, Boron-Kaczmarska A. Characteristics of HIV-1 non-B subtype infections in northwest Poland. J Med Virol. 2010 Aug;82(8):1306-13.
27. Abecasis AB, Wensing AM, Paraskevis D, Vercauteren J, Theys K, Van de Vijver DA, et al. HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics. Retrovirology. 2013;10:7.
28. Stanczak GP, Stanczak JJ, Marczynska M, Firlag-Burkacka E, Wiercinska-Drapalo A, Leszczyszyn-Pynka M, et al. Evolving patterns of HIV-1 transmitted drug resistance in Poland in the years 2000-2008. J Med Virol. 2010;82(7):1291-4.
29. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, de Luca A, Palmisano L, Paraskevis D, et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev. 2011;13(2):77-108.